56. Behcet disease Clinical trials / Disease details
Clinical trials : 81 / Drugs : 107 - (DrugBank : 30) / Drug target genes : 36 - Drug target pathways : 116
Showing 1 to 10 of 81 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05767047 (ClinicalTrials.gov) | March 10, 2023 | 8/3/2023 | A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Diseaseor Juvenile Psori ... | A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of A ... | Behçet's Disease;Juvenile Psoriatic Arthritis | Drug: Apremilast | Amgen | NULL | Not yet recruiting | 5 Years | 18 Years | All | 48 | Phase 3 | NULL |
| 2 | EUCTR2022-003024-41-ES (EUCTR) | 25/01/2023 | 25/11/2022 | Apremilast study in children with active oral ulcers associated with Behçet's Disease or Juvenile Psoriatic Arthritis Apremilast study in children with active oral ulcers associated with Behçet's Diseaseor Juvenile Pso ... | A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet’s Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of A ... | Subjects with active Behçet's Disease or Juvenile Psoriatic Arthritis MedDRA version: 21.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866 MedDRA version: 20.0;Classification code 10079454;Term: Systemic juvenile idiopathic arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Subjects with active Behçet's Diseaseor Juvenile Psoriatic Arthritis MedDRA version: 21.1;Level: LLT ... | Trade Name: Otezla Product Name: Apremilast 20 mg Product Code: AMG 407 INN or Proposed INN: Apremilast Trade Name: Otezla Product Name: Apremilast 30 mg Product Code: AMG 407 INN or Proposed INN: Apremilast Product Name: Apremilast Product Code: AMG 407 INN or Proposed INN: Apremilast Trade Name: Otezla Product Name: Apremilast20 mg Product Code: AMG 407 INN or Proposed INN: Apremilast T ... | Amgen Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 3 | France;Greece;Spain;Turkey;Israel;United Kingdom;Italy;Switzerland | ||
| 3 | NCT05683626 (ClinicalTrials.gov) | December 15, 2022 | 4/1/2023 | Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag University Hospital Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag ... | Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag University Hospital Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag ... | Uveitis | Drug: Humira | Sohag University | NULL | Recruiting | 18 Years | 40 Years | All | 40 | Egypt | |
| 4 | ChiCTR2100052808 | 2022-01-01 | 2021-11-05 | Mechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote macrophage pyrosis to promote behcet disease progression Mechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote ma ... | Mechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote macrophage pyrosis to promote behcet disease progression Mechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote ma ... | Behcet's disease | Control group:No;Active period Behcet's disease(BD) group:No;Remission period BD group:No; | Huadong Hospital of Fudan University | NULL | Recruiting | 18 | 55 | Both | Control group:20;Active period Behcet's disease(BD) group:20;Remission period BD group:20; | China | |
| 5 | NCT04528082 (ClinicalTrials.gov) | September 9, 2021 | 24/8/2020 | Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN) A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed ... | Behçet Disease | Drug: Apremilast;Drug: Placebo | Amgen | NULL | Recruiting | 2 Years | 17 Years | All | 60 | Phase 3 | France;Greece;Israel;Italy;Spain;Switzerland;United Kingdom |
| 6 | EUCTR2019-002787-27-IT (EUCTR) | 24/05/2021 | 07/06/2021 | Apremilast study in children with active oral ulcers associated with Behçet's Disease | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled,Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN) - BEAN A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled,Parallel Group Study, Followed ... | Subjects with active Behçet's Disease MedDRA version: 21.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Subjects with active Behçet's Disease MedDRA version: 21.1;Level: LLT;Classification code 10004212;T ... | Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG Product Name: Apremilast Product Code: [AMG407] INN or Proposed INN: Apremilast Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG Product Name: Apremilast Product Code: [AMG407] INN or Proposed INN: Apremilast Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG Product Name: Apremilast Product Code: [AMG 407] INN or Proposed INN: Apremilast Product Name: Apremilast Product Code: [AMG407] INN or Proposed INN: Apremilast Trade Name: OTEZLA- 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) ... | AMGEN INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 3 | France;Greece;Israel;Netherlands;Switzerland;Italy | ||
| 7 | EUCTR2019-002787-27-GR (EUCTR) | 20/05/2021 | 07/05/2021 | Apremilast study in children with active oral ulcers associated with Behçet’s Disease | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet’s Disease (BEAN) A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed ... | Subjects with active Behçet’s Disease MedDRA version: 21.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Subjects with active Behçet’s Disease MedDRA version: 21.1;Level: LLT;Classification code 10004212;T ... | Trade Name: Otezla Product Name: Apremilast 10 mg Product Code: AMG-407 INN or Proposed INN: Apremilast Trade Name: Otezla Product Name: Apremilast 20 mg Product Code: AMG-407 INN or Proposed INN: Apremilast Trade Name: Otezla Product Name: Apremilast 30 mg Product Code: AMG-407 INN or Proposed INN: Apremilast Product Name: Apremilast Product Code: AMG407 INN or Proposed INN: Apremilast Trade Name: Otezla Product Name: Apremilast10 mg Product Code: AMG-407 INN or Proposed INN: Apremilast T ... | Amgen Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 3 | France;Greece;Israel;Netherlands;Switzerland | ||
| 8 | ChiCTR2100045463 | 2021-05-01 | 2021-04-15 | Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm study Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interv ... | Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm study Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interv ... | intestinal Beh?et's disease | One-armed intervention group:adalimumab; | The First Affiliated Hospital, College of Medicine, Zhejiang University | NULL | Recruiting | 18 | 70 | Both | One-armed intervention group:30; | Phase 4 | China |
| 9 | ChiCTR2100044593 | 2021-03-15 | 2021-03-24 | Clinical study of endoscopic treatment for Patients with intestinal Behcet's disease having poor response to conventional treatment Clinical study of endoscopic treatment for Patients with intestinal Behcet's diseasehaving poor resp ... | Clinical study of endoscopic treatment for Patients with intestinal Behcet's disease having poor response to conventional treatment Clinical study of endoscopic treatment for Patients with intestinal Behcet's diseasehaving poor resp ... | intestinal Behcet's disease | Single group:Endoscopic injection of triamcinolone acetonide; | The First Affiliated Hospital of Sun Yat-Sen University | ,NULL | Recruiting | 16 | 70 | Both | Single group:30; | China | |
| 10 | ITMCTR2000003766 | 2021-01-01 | 2020-08-27 | Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatme ... | Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatme ... | Behcet's Disease | experimental group:Shen's Qinlian Soil Fuling Granules + Thalidomide Tablets;control group:placebo + Thalidomide Tablets ; experimental group:Shen's Qinlian Soil Fuling Granules + ThalidomideTablets;control group:placebo + ... | Shanghai Traditional Chinese Medicine Hospital | NULL | Pending | 16 | 70 | Both | experimental group:60;control group:60; | China |